focused on the ICB predictive power of Neu subclusters within the NSCLC TME specifically, they defined a 38-gene encompassing tissue-resident Neu signature that was associated with anti-PD-L1 therapy failure in the randomized POPLAR and OAK clinical trials (22). The gene discussed is CD274; the disease is non-small cell lung carcinoma.